File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin

TitleSuccessful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin
Authors
KeywordsHepatitis C
Interferon
Kidney transplantation
Ribavirin
Issue Date2003
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
Journal Of Hepatology, 2003, v. 39 n. 5, p. 875-878 How to Cite?
AbstractThe management of acute hepatitis C virus (HCV) infection after renal transplantation (RT) remains controversial, due to the potential risk of interferon-induced graft dysfunction. There is little experience with combined interferon and ribavirin therapy in this group of patients. We treated four consenting RT recipients who developed acute de novo HCV infection with a combination of interferon-alpha 2b and ribavirin. After 48 weeks' treatment, sustained virologic and biochemical remission were achieved in three patients infected with HCV genotypes 1a, 2, and 6a, respectively. The median time from treatment onset to ALT normalization was 8 weeks. The fourth patient was a non-responder infected with genotype 1b. Dose-dependent hemolysis was the most frequent side-effect. No patient developed allograft dysfunction. Our experience indicates that the judicious use of combined interferon and ribavirin can be considered in selected RT recipients with severe acute hepatitis C infection. © 2003 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/76940
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTang, Sen_HK
dc.contributor.authorCheng, IKPen_HK
dc.contributor.authorLeung, VKSen_HK
dc.contributor.authorKuok, UIen_HK
dc.contributor.authorTang, AWCen_HK
dc.contributor.authorHo, YWen_HK
dc.contributor.authorLai, KNen_HK
dc.contributor.authorChan, TMen_HK
dc.date.accessioned2010-09-06T07:26:33Z-
dc.date.available2010-09-06T07:26:33Z-
dc.date.issued2003en_HK
dc.identifier.citationJournal Of Hepatology, 2003, v. 39 n. 5, p. 875-878en_HK
dc.identifier.issn0168-8278en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76940-
dc.description.abstractThe management of acute hepatitis C virus (HCV) infection after renal transplantation (RT) remains controversial, due to the potential risk of interferon-induced graft dysfunction. There is little experience with combined interferon and ribavirin therapy in this group of patients. We treated four consenting RT recipients who developed acute de novo HCV infection with a combination of interferon-alpha 2b and ribavirin. After 48 weeks' treatment, sustained virologic and biochemical remission were achieved in three patients infected with HCV genotypes 1a, 2, and 6a, respectively. The median time from treatment onset to ALT normalization was 8 weeks. The fourth patient was a non-responder infected with genotype 1b. Dose-dependent hemolysis was the most frequent side-effect. No patient developed allograft dysfunction. Our experience indicates that the judicious use of combined interferon and ribavirin can be considered in selected RT recipients with severe acute hepatitis C infection. © 2003 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhepen_HK
dc.relation.ispartofJournal of Hepatologyen_HK
dc.rightsJournal of Hepatology. Copyright © Elsevier BV.en_HK
dc.subjectHepatitis Cen_HK
dc.subjectInterferonen_HK
dc.subjectKidney transplantationen_HK
dc.subjectRibavirinen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAlanine Transaminase - metabolismen_HK
dc.subject.meshAntiviral Agents - administration & dosage - adverse effects - therapeutic useen_HK
dc.subject.meshDose-Response Relationship, Drugen_HK
dc.subject.meshDrug Therapy, Combinationen_HK
dc.subject.meshGenotypeen_HK
dc.subject.meshHemolysisen_HK
dc.subject.meshHepacivirus - geneticsen_HK
dc.subject.meshHepatitis C - drug therapy - etiology - virologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshInterferon-alpha - administration & dosage - adverse effects - therapeutic useen_HK
dc.subject.meshKidney Transplantation - adverse effectsen_HK
dc.subject.meshLiver - enzymologyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshRecombinant Proteinsen_HK
dc.subject.meshRibavirin - administration & dosage - adverse effects - therapeutic useen_HK
dc.subject.meshTime Factorsen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleSuccessful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirinen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0168-8278&volume=39&spage=875&epage=878&date=2003&atitle=Successful+treatment+of+hepatitis+C+after+kidney+transplantation+with+combined+interferon+alpha-2b+and+ribavirinen_HK
dc.identifier.emailTang, S: scwtang@hku.hken_HK
dc.identifier.emailLai, KN: knlai@hku.hken_HK
dc.identifier.emailChan, TM: dtmchan@hku.hken_HK
dc.identifier.authorityTang, S=rp00480en_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.identifier.authorityChan, TM=rp00394en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0168-8278(03)00358-1en_HK
dc.identifier.pmid14568274-
dc.identifier.scopuseid_2-s2.0-0242521535en_HK
dc.identifier.hkuros87431en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0242521535&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume39en_HK
dc.identifier.issue5en_HK
dc.identifier.spage875en_HK
dc.identifier.epage878en_HK
dc.identifier.isiWOS:000186441500029-
dc.publisher.placeNetherlandsen_HK
dc.identifier.scopusauthoridTang, S=7403437082en_HK
dc.identifier.scopusauthoridCheng, IKP=7102537483en_HK
dc.identifier.scopusauthoridLeung, VKS=7102336049en_HK
dc.identifier.scopusauthoridKuok, UI=55443705200en_HK
dc.identifier.scopusauthoridTang, AWC=7201845919en_HK
dc.identifier.scopusauthoridHo, YW=7402555047en_HK
dc.identifier.scopusauthoridLai, KN=7402135706en_HK
dc.identifier.scopusauthoridChan, TM=7402687700en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats